Abstract：
Antipsychotics (APs) are the cornerstone of treatment for schizophrenia (SCZ) spectrum disorders. Previous research suggests that there may be a positive association between AP-induced weight gain and/or dyslipidemia and improvement in psychiatric symptoms, often referred to as a \"metabolic threshold\". To determine whether a similar relationship exists for glucose parameters, we conducted a systematic search in six databases from inception to June 2022 for all longitudinal studies that directly examined the relationship between changes in glucose-related outcomes and changes in psychopathology among patients with SCZ treated with APs. We identified 10 relevant studies and one additional study that considered cognition. In most cases, we found that increased levels of fasting glucose and insulin following treatment were associated with clinical improvement. These findings contribute to existing literature that could suggest a common mechanism between AP action and metabolic side effects and support a need for additional work aimed at exploring the validity of a glucose-psychopathology relation in SCZ.
摘要：
抗精神病药(AP)是治疗精神分裂症(SCZ)谱系障碍的基石。先前的研究表明，AP诱导的体重增加和/或血脂异常与精神症状的改善之间可能存在正相关。通常被称为“代谢阈值”。为了确定葡萄糖参数是否存在类似的关系，从开始到2022年6月,我们在6个数据库中进行了系统检索,查找了所有纵向研究,这些研究直接检查了接受AP治疗的SCZ患者中葡萄糖相关结局的变化与精神病理学变化之间的关系.我们确定了10项相关研究和一项考虑认知的额外研究。在大多数情况下,我们发现治疗后空腹血糖和胰岛素水平升高与临床改善相关.这些发现有助于现有文献，这些文献可能表明AP作用与代谢副作用之间的共同机制，并支持需要进行旨在探索SCZ中葡萄糖-精神病理学关系有效性的其他工作。
